July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural pacemaker ...

Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial has commenced enrollment in Europe. The first patient was treated by Professor Dr. Marianne Brodmann and Dr. Peter Reif at Medical University Graz, Austria.

July 26, 2017 — The U.S. Senate voted Monday, with a tiebreaking vote from Vice President Mike Pence, to begin debate on ...

July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are ...

Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests, researchers from the University of Illinois at Chicago have found the disease affects other organs in 40 percent of known patients with cardiac sarcoidosis. The findings are published in the Journal of Nuclear Cardiology.

Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation (PVI) with the Arctic Front Advance Cryoballoon in patients with symptomatic paroxysmal atrial fibrillation (AF) prior to treatment with anti-arrhythmic medications. The first patient in the trial was recently enrolled at The Ohio State University Wexner Medical Center by Jaret Tyler, M.D.

Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the benefits of Biotronik's DX technology to heart failure patients. DX eliminates the need for an atrial lead while still providing physicians with critical diagnostic information based on a true atrial signal.